New therapy for pancreatic cancer based on extracellular vesicles

Biomedicine & Pharmacotherapy - Tập 162 - Trang 114657 - 2023
Salomé Araujo-Abad1,2,3, Antonio Manresa-Manresa1, Enrique Rodríguez-Cañas2, María Fuentes- Baile1, Pilar García-Morales2, Ricardo Mallavia2, Miguel Saceda1,2, Camino de Juan Romero1,2
1Unidad de Investigación, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Hospital General Universitario de Elche, Camí de l'Almazara 11, Elche, 03203 Alicante, Spain
2Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández, Avda, Universidad s/n, Ed. Torregaitán, Elche, 03202 Alicante, Spain
3Centro de Biotecnología, Universidad Nacional de Loja, Avda. Pio Jaramillo Alvarado s/n, Loja, 110111 Loja, Ecuador

Tài liệu tham khảo

Miller, 2016, Cancer treatment and survivorship statistics, 2016, CA Cancer J. Clin., 66, 271, 10.3322/caac.21349 Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660 Adamska, 2017, Pancreatic ductal adenocarcinoma: current and evolving therapies, Int. J. Mol. Sci., 18 Abbruzzese, 2008, Adjuvant therapy for surgically resected pancreatic adenocarcinoma, JAMA, 299, 1066, 10.1001/jama.299.9.1066 Fang, 2015, Temozolomide nanoparticles for targeted glioblastoma therapy, ACS Appl. Mater. Interfaces, 7, 6682, 10.1021/am5092165 Gronchi, 2021, Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 32, 1348, 10.1016/j.annonc.2021.07.006 Casali, 2018, Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 29, iv79, 10.1093/annonc/mdy310 Nabors, 2020, Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Canc. Netw., 18, 1537, 10.6004/jnccn.2020.0052 von Mehren, 2020, NCCN guidelines insights: soft tissue sarcoma, Version 1.2021, J. Natl. Compr. Cancer Netw., 18, 1605 Swetter, 2021, NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021, J. Natl. Compr. Cancer Netw., 19, 364, 10.6004/jnccn.2021.0018 Pavel, 2020, Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 31, 844, 10.1016/j.annonc.2020.03.304 Stupp, 2014, High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 25, iii93, 10.1093/annonc/mdu050 Moore, 1998, A phase II study of temozolomide in advanced untreated pancreatic cancer, Invest. N. Drugs, 16, 77, 10.1023/A:1006043332368 Ostermann, 2004, Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients, Clin. Cancer Res., 10, 3728, 10.1158/1078-0432.CCR-03-0807 Sengupta, 2012, Impact of temozolomide on immune response during malignant glioma chemotherapy, Clin. Dev. Immunol., 2012, 10.1155/2012/831090 Chamberlain, 2014, Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas, Expert Rev. Neurother., 10, 1537, 10.1586/ern.10.32 Trinh, 2009, The safety of temozolomide in the treatment of malignancies, Expert Opin. Drug Saf., 8, 493, 10.1517/14740330902918281 Chan-Penebre, 2015, A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models, Nat. Chem. Biol., 11, 432, 10.1038/nchembio.1810 Stopa, 2015, The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond, Cell. Mol. life Sci., 72, 2059, 10.1007/s00018-015-1847-9 Wang, 2018, Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery, J. Med. Chem., 61, 9429, 10.1021/acs.jmedchem.8b00598 Vinet, 2019, Protein arginine methyltransferase 5: a novel therapeutic target for triple‐negative breast cancers, Cancer Med, 8, 2428, 10.1002/cam4.2114 Singh, 2016, Exosome-mediated transfer of Αvβ3 integrin from tumorigenic to nontumorigenic cells promotes a migratory phenotype, Mol. Cancer Res., 14, 1136, 10.1158/1541-7786.MCR-16-0058 Colombo, 2014, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles, Annu. Rev. Cell Dev. Biol., 30, 255, 10.1146/annurev-cellbio-101512-122326 Wang, 2019, Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer, Mol. Carcinog., 58, 674, 10.1002/mc.22960 Araujo-Abad, 2022, Biomedical application of small extracellular vesicles in cancer treatment, Adv. Drug Deliv. Rev., 182, 10.1016/j.addr.2022.114117 Qiao, 2020, Tumor cell-derived exosomes home to their cells of origin and can be used as trojan horses to deliver cancer drugs, Theranostics, 10, 3474, 10.7150/thno.39434 Batrakova, 2015, Using exosomes, naturally-equipped nanocarriers, for drug delivery, J. Control. Release, 219, 396, 10.1016/j.jconrel.2015.07.030 Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 Nam, 2018, Drug delivery nanosystems for the localized treatment of glioblastoma multiforme, Mater. (Basel), 11 Bazeed, A.Y.; Day, C.M.; Garg, S. Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies. Cancers 2022, Vol. 14, Page 4257 2022, 14, 4257, doi:10.3390/CANCERS14174257. Fuentes-Baile, 2020, CLyta-DAAO, free and immobilized in magnetic nanoparticles, induces cell death in human cancer cells, Biomolecules, 10, 222, 10.3390/biom10020222 Ventero, 2019, Radiotherapy resistance acquisition in glioblastoma. Role of SOCS1 and SOCS3, PLoS One, 14 Neira, 2022, Biochemical and biophysical characterization of PADI4 supports its involvement in cancer, Arch. Biochem. Biophys., 717, 10.1016/j.abb.2022.109125 Dexter, 1982, Establishment and characterization of two human pancreatic cancer cell lines tumorigenic in athymic mice, Cancer Res., 42, 2705 Fuentes-Baile, 2020, Differential effects of IGF-1R small molecule tyrosine kinase inhibitors BMS-754807 and OSI-906 on human cancer cell lines, Cancers (Basel), 12, 1, 10.3390/cancers12123717 Fuentes-Baile, 2021, Clyta-daao chimeric enzyme bound to magnetic nanoparticles. A new therapeutical approach for cancer patients?, Int. J. Mol. Sci., 22, 1, 10.3390/ijms22031477 Fuentes‐baile, 2020, Cell death mechanisms induced by CLytA‐DAAO chimeric enzyme in human tumor cell lines, Int. J. Mol. Sci., 21, 1, 10.3390/ijms21228522 Araujo-Abad, S.; Manresa-Manresa, A.; Rodríguez-Cañas, E.; Fuentes-Baile, M.; García-Morales, P.; Mallavia, R.; Saceda, M.; De, C.; Romero, J. Glioblastoma-Derived Small Extracellular Vesicles: Nanoparticles for Glioma Treatment. Int. J. Mol. Sci. 2023, Vol. 24, Page 5910 2023, 24, 5910, doi:10.3390/IJMS24065910. Zhang, 2019, Exosomes: biogenesis, biologic function and clinical potential, Cell Biosci., 9, 1, 10.1186/s13578-019-0282-2 Sokolova, 2011, Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy, Colloids Surf. B Biointerfaces, 87, 146, 10.1016/j.colsurfb.2011.05.013 Sarantis, 2020, Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy, World J. Gastrointest. Oncol., 12, 173, 10.4251/wjgo.v12.i2.173 Principe, 2021, The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy, Front. Oncol., 11, 2773, 10.3389/fonc.2021.688377 Casper, 1994, Phase II trial of gemcitabine (2,2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas, Invest. N. Drugs, 12, 29, 10.1007/BF00873232 Carmichael, 1996, Phase II study of gemcitabine in patients with advanced pancreatic cancer, Br. J. Cancer, 73, 101, 10.1038/bjc.1996.18 Moore, 1996, Activity of gemcitabine in patients with advanced pancreatic carcinoma a review BACKGROUND. In early phase I1 trials in advanced pancreatic cancer, Gemcitabine. Cancer, 78, 633, 10.1002/(SICI)1097-0142(19960801)78:3+<633::AID-CNCR8>3.0.CO;2-B Robertson, 2016, Essential medicines for cancer: WHO recommendations and national priorities, Bull. World Health Organ, 94, 742, 10.2471/BLT.15.163998 Wei, 2020, Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells, Proc. Natl. Acad. Sci. U. S. A., 117, 28068, 10.1073/pnas.2009899117 Braun, 2017, Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma, Cancer Cell, 32, 411, 10.1016/j.ccell.2017.08.018 Liu, 2021, EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma, Exp. Eye Res., 202, 10.1016/j.exer.2020.108286 Xi, 2021, Drug loading techniques for exosome-based drug delivery systems, Pharmazie, 76, 61 Wu, 2021, Preservation of small extracellular vesicles for functional analysis and therapeutic applications: a comparative evaluation of storage conditions, Drug Deliv., 28, 162, 10.1080/10717544.2020.1869866 Siegel, 2016, Cancer Statistics, 2016, CA Cancer J. Clin., 66, 7, 10.3322/caac.21332 Li, 2016, Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy, Oncotarget, 7, 24585, 10.18632/oncotarget.8358 Howlader, N.; Noone, A.; Krapcho, M. SEER Cancer Statistics Review (CSR) 1975–2017. National Cancer Institute Available online: https://seer.cancer.gov/archive/csr/1975_2017/ (accessed on 30 September 2022). Conroy, 2018, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N. Engl. J. Med., 379, 2395, 10.1056/NEJMoa1809775 Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N. Engl. J. Med., 350, 1200, 10.1056/NEJMoa032295 Laviano, 2005, Therapy insight: cancer anorexia-cachexia syndrome--when all you can eat is yourself, Nat. Clin. Pract. Oncol., 2, 158, 10.1038/ncponc0112 Grossberg, 2020, Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma, Ca. Cancer J. Clin., 70, 375, 10.3322/caac.21626 Babic, 2019, Post diagnosis loss of skeletal muscle, but not adipose tissue, is associated with shorter survival of patients with advanced pancreatic cancer, Cancer Epidemiol. Biomark. Prev., 28, 2062, 10.1158/1055-9965.EPI-19-0370 Kays, 2018, Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer, J. Cachex. Sarcopenia Muscle, 9, 673, 10.1002/jcsm.12307 Bachmann, 2008, Cachexia worsens prognosis in patients with resectable pancreatic cancer, J. Gastrointest. Surg., 12, 1193, 10.1007/s11605-008-0505-z Hendifar, 2016, Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma, PLoS One, 11, 10.1371/journal.pone.0152172 Görgens, 2022, Identification of storage conditions stabilizing extracellular vesicles preparations, J. Extracell. Vesicles, 11, 10.1002/jev2.12238 Sivanantham, 2022, Impact of storage conditions on EV integrity/surface markers and cargos, Life, 12, 697, 10.3390/life12050697 Zhang, 2020, Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications, Int. J. Nanomed., 15, 6917, 10.2147/IJN.S264498